Elementis: The Quiet Transformation That Smart Money Is Tracking
Strong stock · UK · ELEMENTIS PLC ORD 5P (ELM.L) · Analysis as of 2026-07-24
A PEG ratio of just 0.02. A Personal Care margin north of 32%. A share buyback completed, dividends raised, and strategic targets hit ahead of schedule. Elementis PLC is quietly ticking every box — and the market may not have fully caught on yet.
Most transformations in specialty chemicals take years to show up in the numbers. Elementis PLC has managed to make theirs land early — and the market is only beginning to price it in.
Trading at £169.40, with a P/E of 21.18x and a PEG ratio of a remarkable 0.02, the London-listed specialty chemicals group is presenting an intriguing case for those willing to look beyond the headline revenue figures and dig into the structural shift unfolding beneath the surface.
---
The Fundamentals: A Business Remade
The story at Elementis is one of deliberate, disciplined reinvention. Over the past two years, management has stripped out non-core assets — most notably the Talc division — and repositioned the group as a pure-play specialty chemicals business anchored in two high-quality segments: Personal Care and Coatings.
The FY 2025 results, presented in March 2026, told a compelling story. Group revenue came in at $597.5 million, while adjusted operating profit rose 4.6% to $126.7 million, pushing the adjusted operating margin to 21.2%. The standout, however, was Personal Care — a segment now operating at a 32.4% adjusted operating margin, up a striking 410 basis points year-on-year. That kind of margin trajectory in a specialty chemical segment typically commands a premium multiple.
The Coatings division, despite a 4.3% revenue decline in softer end markets, held its margin at a resilient 18.9% — evidence of the pricing discipline and cost management the management team has been executing.
| Metric | FY 2025 | |---|---| | Group Revenue | $597.5m | | Adj. Operating Profit | $126.7m | | Adj. Operating Margin | 21.2% | | Personal Care Margin | 32.4% | | Coatings Margin | 18.9% | | Net Debt / EBITDA | 1.3x | | Full-Year Dividend | 4.3¢ (+7.5% YoY) |
The capital returns story adds further conviction. Elementis completed a £40 million share buyback in 2025 and raised its full-year dividend by 7.5% to 4.3 cents per share. Net debt to EBITDA now sits at a comfortable 1.3x — leaving meaningful capacity for ongoing capital returns or bolt-on investment.
Perhaps the most telling signal? The company achieved its 2026 financial targets — operating margins above 19%, cash conversion above 90%, and ROCE above 20% — ahead of schedule.
Q1 2026: Momentum Holding
The first quarter 2026 trading update, published in late April, confirmed the trajectory. Organic group revenue rose approximately 2%, while adjusted operating profit and margins expanded strongly year-on-year. Coatings saw margins lift materially on cost savings and improved volumes. In Personal Care, pricing strength and a favourable product mix offset modest softness in the Americas.
The pending disposal of the pharma manufacturing unit to Associated British Foods — expected to complete in the second quarter of 2026 — adds a further near-term catalyst, enabling a cleaner balance sheet and sharper operational focus.
Management explicitly maintained full-year 2026 guidance, despite the uncertain macro backdrop — a statement of quiet confidence that institutional investors tend to notice.
---
The Technical Picture: Building a Base
From a technical standpoint, Elementis has navigated a 52-week range of £120.20 to £179.60, and at £169.40 it sits in the upper quartile of that range. The price action reflects a stock that has steadily recovered from its lows and is now compressing near resistance — the kind of constructive base-building pattern that often precedes a directional move.
The broader momentum picture supports the fundamental narrative. The stock's proximity to its 52-week high, combined with sustained earnings upgrades and consistent management delivery, creates the conditions for continued positive price discovery.
Analyst sentiment is broadly constructive across the seven-strong coverage universe — not a single negative rating — with a consensus 12-month price target of approximately £199.44 and estimates ranging as high as £211. At the current price, that implies meaningful headroom to consensus fair value.
---
The PEG Ratio: A Number Worth Pausing On
A PEG ratio of 0.02 is not a typo. It reflects the extent to which the market has yet to fully credit Elementis for the earnings growth embedded in its transformation. Historically, PEG ratios below 1.0 are considered indicative of potential undervaluation relative to growth; at 0.02, the implied disconnect between the current multiple and near-term earnings momentum is striking.
---
The Takeaway
Elementis is a business mid-way through a re-rating. The operational work is largely done — margins are expanding, targets are beaten early, the balance sheet is conservative, and capital is being returned to shareholders. What remains is for the market to fully recognise the new earnings power of a leaner, higher-margin specialty chemicals group.
With interim results due on 30 July 2026, the next data point is close. History suggests that companies with this combination of delivery, momentum, and analyst support tend not to stay quietly undervalued for long.
--- Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a qualified financial advisor before making any investment decisions.